WILEX
Heidelberg Pharma (WILEX) is a German clinical-stage biotech developing antibody-drug conjugates based on its proprietary ATAC platform using Amanitin payload for hematological and solid tumor oncology indications.
- Company typePrivate
- Founded1997
- HeadquartersLadenburg, Germany
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What WILEX does
Heidelberg Pharma AG (operating under legacy name WILEX, ticker etr:WL6) is a German clinical-stage biotechnology company headquartered in Ladenburg with a Munich presence, developing oncology therapeutics based on its proprietary ATAC (Antibody Targeted Amanitin Conjugate) platform. The platform combines the targeting specificity of antibodies with Amanitin, a toxin derived from the green death cap mushroom whose RNA polymerase II inhibition mechanism is described as capable of overcoming drug resistance and eliminating quiescent tumor cells — differentiation versus the more common MMAE/DM1-based ADC payloads. The company operates a portfolio that includes its lead candidate HDP-101 (now in Phase II, with recommended dose determined in April 2026) and additional ATAC candidates targeting hematological and solid tumors.
The company's business model is that of a pre-revenue, development-stage biotech: revenue is not yet derived from commercial product sales but is expected to come from out-licensing, milestone payments and royalties once candidates reach market. Currently the model is sustained by capital markets financing (disclosed rounds include Yorkville Advisors in 2010 and a Series 3 round led by Apax Partners/Earlybird/TVM in 2005) and strategic partnerships. A central commercial vehicle is the collaboration with Telix Pharmaceuticals on TLX250-CDx (Zircaix), a kidney cancer imaging agent that has progressed to FDA BLA filing with priority review and a Phase III ZIRCON-CP trial in China. Customer/partner relationships are therefore concentrated around oncology imaging and ADC co-development rather than end-payor revenue.
Customer-facing activity centers on investigator relations, scientific communications (publications, posters, conferences) and investor/stakeholder disclosure (press releases, AGM, financial calendar). Distribution and pricing details are not publicly disclosed given the absence of approved products; commercialization would be expected to leverage established pharmaceutical distribution networks and specialty oncology channels upon any regulatory approval. The company's competitive advantage is grounded in its patented payload chemistry, its specialized conjugation know-how, and its regulatory progress through multiple INDs and clinical milestones.
WILEX firmographics
Firmographics- Name
- WILEX
- Website
- https://wilex.de
- Company type
- Private
- Founded year
- 1997
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Heidelberg Pharma (WILEX) is a German clinical-stage biotech developing antibody-drug conjugates based on its proprietary ATAC platform using Amanitin payload for hematological and solid tumor oncology indications.
- Ownership category
- akta.pro rank
WILEX industry classification
Industry- Product category
- Biopharmaceutical Oncology Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
- akta.pro secondary industry
- Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches) (HLAAACAF)
Keywords
Where WILEX is headquartered
LocationHeadquarters
- HQ city
- Ladenburg
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
WILEX business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Pipeline Development Revenue: Pre-revenue development stage biotech company focused on developing novel cancer therapies using antibody and small molecule platforms. No commercialized products yet; revenue will be generated upon regulatory approval and commercialization of pipeline candidates.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
WILEX product offering
Product offeringCore offering
WILEX AG is a Munich-based development-stage biotechnology company developing novel cancer therapies through two complementary platforms — antibody-based therapeutics and small molecule therapeutics — targeting specific patient subpopulations defined by the molecular characterization of their primary tumors. The proprietary ATAC technology combines antibodies with the Amanitin toxin from the green death cap mushroom to create antibody-drug conjugates (ADCs) that can overcome drug resistance and eliminate quiescent tumor cells. The pipeline includes HDP-101 in Phase II for hematological and solid tumors, and out-licensed assets such as TLX250-CDx (kidney cancer imaging) being advanced with Telix Pharmaceuticals.
Product overview
WILEX AG is a Munich-based biotech company developing novel cancer therapies through two complementary platforms: antibody-based therapeutics and small molecule therapeutics. The company's approach focuses on treating specific patient subpopulations based on molecular characterization of primary tumors, enabling targeted cancer treatment strategies.
Differentiator
Problem solved
Functional benefit
Products and services
- Antibody Platform Antibody-based therapeutic platform developing novel cancer therapies for specific patient subpopulations defined by the molecular characteristics of their primary tumors. Aimed at oncology indications with high unmet need and drug resistance.
- Small Molecule Platform Small molecule-based therapeutic platform developing novel cancer therapies targeting specific patient subpopulations with molecularly characterized tumors, complementary to the Antibody Platform.
- HDP-101 Lead ADC candidate based on the proprietary ATAC platform, being developed for hematological and solid tumors. In Phase II clinical development with recommended Phase II dose determined in April 2026.
- TLX250-CDx (Zircaix) [out-licensed] Out-licensed kidney cancer imaging diagnostic developed with partner Telix Pharmaceuticals; BLA filed with FDA and priority review designation granted, with Phase III ZIRCON-CP trial underway in Chinese patients.
Companies that use WILEX
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles2 records
WILEX technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
WILEX partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Telix PharmaceuticalscoreTelix Pharmaceuticals is a key strategic partner developing TLX250-CDx (Zircaix) for kidney cancer imaging. The partnership involves FDA BLA filing for TLX250-CDx with priority review granted, Phase III ZIRCON-CP trial in Chinese patients, and ongoing regulatory collaboration. This represents a significant out-licensed product candidate in Wilex/Heidelberg Pharma's pipeline.
Scale indicators2 records
Recent moves5 records
Expansion highlights5 records
WILEX competitors and assessment
Company assessmentEmerging players
- Mersana Therapeutics: Mersana Therapeutics is a clinical-stage biotech developing next-generation ADCs with novel payloads and linkers, making it a relevant emerging peer in the ADC oncology space.
- Tubulis: Tubulis is a European biotech developing next-generation ADCs with novel payloads and linkers, making it a directly relevant emerging peer focused on differentiated ADC chemistry.
- Molecular Templates: Molecular Templates develops engineered toxin bodies (ETBs) for oncology, with a similar approach of leveraging novel biological payloads (similar in spirit to Heidelberg Pharma's Amanitin-based ATAC platform).
- Innovent Biologics: Innovent is a China-based biopharmaceutical company with a growing ADC pipeline (including IBI354 and others), representing an emerging peer in the global oncology ADC market.
- CytomX Therapeutics: CytomX develops Probody-drug conjugates — a conditionally activated ADC platform — making it a relevant emerging peer in oncology ADC technology development.
Direct peers
- ADC Therapeutics: ADC Therapeutics is a clinical-stage biotechnology company developing antibody-drug conjugates for hematological and solid tumors, making it a directly comparable ADC-focused peer to Heidelberg Pharma.
- ImmunoGen (now part of AbbVie): ImmunoGen pioneered ADC technology and developed Elahere (mirvetuximab soravtansine); acquired by AbbVie in 2024. It is a directly comparable peer in ADC platform development for oncology.
Broad incumbents
- Daiichi Sankyo: Daiichi Sankyo is a broad incumbent that commercialized Enhertu and datopotamab deruxtecan (with AstraZeneca) using DXd ADC technology — a major competitive force in the ADC market where Heidelberg Pharma operates.
- AstraZeneca: AstraZeneca, in partnership with Daiichi Sankyo, is a broad incumbent commercializing Enhertu and a deep ADC pipeline, making it a key competitive force for Heidelberg Pharma's ATAC platform.
- Pfizer (Seagen): Pfizer's acquisition of Seagen in 2023 brought Adcetris, Padcev, and Tivdak into its portfolio, making it a broad incumbent in the ADC space directly relevant to Heidelberg Pharma's competitive landscape.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
WILEX financial estimates
Financial estimateRevenue estimate
Valuation estimate
WILEX leadership team
Management profileNumber of profiles
WILEX funding detail
Funding detailFunding overview
Funding rounds4 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
WILEX M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about WILEX
What does WILEX do?
WILEX AG is a Munich-based development-stage biotechnology company developing novel cancer therapies through two complementary platforms — antibody-based therapeutics and small molecule therapeutics — targeting specific patient subpopulations defined by the molecular characterization of their primary tumors. The proprietary ATAC technology combines antibodies with the Amanitin toxin from the green death cap mushroom to create antibody-drug conjugates (ADCs) that can overcome drug resistance and eliminate quiescent tumor cells. The pipeline includes HDP-101 in Phase II for hematological and solid tumors, and out-licensed assets such as TLX250-CDx (kidney cancer imaging) being advanced with Telix Pharmaceuticals.
Is WILEX a public or private company?
WILEX is a private company. It is classified as public and is currently operating.
When was WILEX founded?
WILEX was founded in 1997. It employs 51 to 100 people.
Where is WILEX based?
WILEX is headquartered in Ladenburg, Germany, in the Europe region.
How does WILEX make money?
One revenue line is on record: pipeline Development Revenue.
Who are WILEX's main competitors?
Emerging players on record are Mersana Therapeutics, Tubulis, Molecular Templates, Innovent Biologics and CytomX Therapeutics. Direct peers are ADC Therapeutics and ImmunoGen (now part of AbbVie). Broad incumbents are Daiichi Sankyo, AstraZeneca and Pfizer (Seagen).
Does WILEX have an API?
No public API is recorded for WILEX.
What industry is WILEX in?
WILEX's product category is Biopharmaceutical Oncology Therapeutics. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAACAF, Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches). Its NAICS code is 325414 and its SIC code is 2834.